SNDXSyndax PharmaceuticalsSigning up patients
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Acute Myeloid Leukemias
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.6
2 insiders sold shares within a month
Since Jun 1, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 468 (planned)
- Started
- Nov 25, 2025
- Main results expected
- Jun 2029
- Fully finished
- Jan 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event Free Survival
Measured over: Up to 2 years
Measurable Residual Disease Complete Remission Rate
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.6, since 2026-06-01, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07211958 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC